Results 251 to 260 of about 2,980,265 (315)

An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics. [PDF]

open access: yesInt J Toxicol
Sisler JD   +12 more
europepmc   +1 more source

Naphthalene: MAK Value Documentation, addendum - Translation of the German version from 2022. [PDF]

open access: yesMAK Collect Occup Health Saf
Hartwig A   +1 more
europepmc   +1 more source

Testing for carcinogenicity of pharmaceuticals.

open access: yesThe Journal of toxicological sciences, 1997
T, Usui, H, Masuda
openaire   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Carcinogenicity Testing of Drugs

JAMA: The Journal of the American Medical Association, 1980
To the Editor.— I agree with John C. Ballin, MD (242:26, 1979), that the results of studies in which large doses are given to animals for a lifetime do not necessarily mean that "such drugs or chemicals are carcinogenic in man when taken according to label directions." But the studies do not necessarily mean that such drugs or chemicals are not ...
openaire   +2 more sources

Carcinogenicity Testing of Drugs

JAMA: The Journal of the American Medical Association, 1979
To the Editor.— The National Cancer Institute (NCI) has begun a long-term project of testing commonly used drugs for their possible carcinogenic effect in animals. In conducting these tests, the NCI uses a standard protocol that involves giving drugs for long periods (generally lifetime feeding) in large doses to mice, rats, and other experimental ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy